Prime Medicine, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRME research report →
About the company
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule.
- CEO
- Allan Reine
- IPO
- 2022
- Employees
- 214
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $698.99M
- P/E
- -3.05
- P/S
- 173.27
- P/B
- 8.94
- EV/EBITDA
- -3.93
- Div Yield
- 0.00%
- Gross Margin
- -1082.70%
- Op Margin
- -5121.76%
- Net Margin
- -4917.55%
- ROE
- -188.82%
- ROIC
- -77.39%
- Revenue
- $4.63M · 55.28%
- Net Income
- $-201,142,000 · -2.69%
- EPS
- $-1.35 · 18.26%
- Op Income
- $-208,350,000
- FCF YoY
- -28.38%
- 52W High
- $6.94
- 52W Low
- $2.67
- 50D MA
- $3.27
- 200D MA
- $3.93
- Beta
- 2.27
- Avg Volume
- 2.69M
Get TickerSpark's AI analysis on PRME
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 5, 26 | Schenkein David P | other | 75,000 |
| Jun 5, 26 | Marrazzo Jeffrey D | other | 75,000 |
| Jun 5, 26 | NELSEN ROBERT | other | 75,000 |
| Jun 5, 26 | Kelly Michael Aaron | other | 75,000 |
| Jun 5, 26 | Foster-Cheek Kaye I | other | 75,000 |
| Jun 5, 26 | Chung Wendy | other | 75,000 |
| Jun 5, 26 | Cahill Thomas | other | 75,000 |
| Apr 16, 26 | Makhni Svetlana Ni | other | 800,000 |
| Apr 16, 26 | Makhni Svetlana Ni | other | 0 |
| Feb 26, 26 | Reine Allan | other | 1,300,000 |
Our PRME coverage
Recent articles, reports, and earnings notes.
Want a deeper read on PRME?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.